Table 2 Haemoglobin response and clinical parameters
Clinical paramaters | Response to EPO, N(%) | Chi square | |
|---|---|---|---|
Non Response | Response | P value | |
Response to Glivec | |||
SD + PR | 9(56.3%) | 18(100%) | 0.02 |
PD | 7(44%) | 0(0%) | |
Male | 9(56.3%) | 9(50%) | 0.7 |
Female | 7(44%) | 9(50%) | |
Liver metastases | |||
No | 1(6.3%) | 5(28%) | 0.2 |
Yes | 15(94%) | 13(72%) | |
Lung metastases | |||
No | 14(875%) | 16(89%) | 1.0 |
Yes | 2(12.5%) | 2(11%) | |
Peritoneal metastases | |||
No | 3(19%) | 6(33.5%) | 0.44 |
Yes | 13(81.5%) | 12(66.5%) | |
Imatinib dose | |||
400 mg/d | 9(56.3%) | 16(89%) | 0.05 |
800 mg/d | 7(44%) | 2(11%) | |
Age | |||
≥ 60 years | 8(50%) | 9(50%) | 1.0 |
< 60 years | 8(50%) | 9(50%) | |